KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
130 hedge funds and large institutions have $467M invested in KalVista Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 50 increasing their positions, 29 reducing their positions, and 19 closing their positions.
72% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 29
53% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 19
7% more funds holding
Funds holding: 122 → 130 (+8)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.34% less ownership
Funds ownership: 112.01% → 111.68% (-0.34%)
17% less capital invested
Capital invested by funds: $561M → $467M (-$93.5M)
94% less call options, than puts
Call options by funds: $115K | Put options by funds: $1.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$14.2M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$12.4M |
| 3 |
SC
Stempoint Capital
New York
|
+$10.3M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$7.97M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$7.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$11.6M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$10.4M |
| 3 |
FTM
First Turn Management
Del Mar,
California
|
-$4.11M |
| 4 |
BlackRock
New York
|
-$2.05M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$1.05M |
KALV Hedge Fund Activity: Q4 2024 in Review
130 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q4 2024, worth a combined $467M — down 17% from $561M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new KALV positions and 19 closed out — a net gain of 10 holders — while 50 added to existing stakes and 29 trimmed.
The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $14.2M. The largest seller was Adage Capital Partners, cutting an estimated $11.6M.
- 130 institutional investors held KalVista Pharmaceuticals (KALV) as of Q4 2024, up from 122 in Q3 2024.
- Funds reported $467M of KalVista Pharmaceuticals stock for Q4 2024, down 17% quarter-over-quarter.
- 29 funds opened new KalVista Pharmaceuticals positions in Q4 2024 and 19 closed out, a net change of +10 holders.
- The largest KalVista Pharmaceuticals buyer in Q4 2024 was Octagon Capital Advisors, an estimated $14.2M added.
- The largest KalVista Pharmaceuticals seller in Q4 2024 was Adage Capital Partners, an estimated $11.6M sold.
Based on aggregated 13F filings for Q4 2024.